|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:EZH2-RUFY2 (FusionGDB2 ID:28023) |
Fusion Gene Summary for EZH2-RUFY2 |
Fusion gene summary |
Fusion gene information | Fusion gene name: EZH2-RUFY2 | Fusion gene ID: 28023 | Hgene | Tgene | Gene symbol | EZH2 | RUFY2 | Gene ID | 2146 | 55680 |
Gene name | enhancer of zeste 2 polycomb repressive complex 2 subunit | RUN and FYVE domain containing 2 | |
Synonyms | ENX-1|ENX1|EZH2b|KMT6|KMT6A|WVS|WVS2 | RABIP4R|ZFYVE13 | |
Cytomap | 7q36.1 | 10q21.3 | |
Type of gene | protein-coding | protein-coding | |
Description | histone-lysine N-methyltransferase EZH2enhancer of zeste homolog 2lysine N-methyltransferase 6 | RUN and FYVE domain-containing protein 2Run- and FYVE-domain containing proteinantigen MU-RMS-40.17rab4-interacting protein related | |
Modification date | 20200329 | 20200313 | |
UniProtAcc | Q15910 | . | |
Ensembl transtripts involved in fusion gene | ENST00000478654, ENST00000460911, ENST00000350995, ENST00000320356, ENST00000541220, ENST00000476773, ENST00000483967, ENST00000536783, | ENST00000388768, ENST00000602465, ENST00000265865, ENST00000399200, ENST00000454950, ENST00000472394, ENST00000342616, | |
Fusion gene scores | * DoF score | 9 X 9 X 5=405 | 9 X 9 X 5=405 |
# samples | 9 | 11 | |
** MAII score | log2(9/405*10)=-2.16992500144231 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(11/405*10)=-1.88041838424733 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: EZH2 [Title/Abstract] AND RUFY2 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | EZH2(148504703)-RUFY2(70136641), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | EZH2 | GO:0000122 | negative regulation of transcription by RNA polymerase II | 20154697 |
Hgene | EZH2 | GO:0010718 | positive regulation of epithelial to mesenchymal transition | 20154697 |
Hgene | EZH2 | GO:0043406 | positive regulation of MAP kinase activity | 20154697 |
Hgene | EZH2 | GO:0043547 | positive regulation of GTPase activity | 20154697 |
Hgene | EZH2 | GO:0045814 | negative regulation of gene expression, epigenetic | 20154697 |
Hgene | EZH2 | GO:0070734 | histone H3-K27 methylation | 24474760 |
Hgene | EZH2 | GO:0071902 | positive regulation of protein serine/threonine kinase activity | 20154697 |
Fusion gene breakpoints across EZH2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across RUFY2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChiTaRS5.0 | N/A | CA417159 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
Top |
Fusion Gene ORF analysis for EZH2-RUFY2 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
intron-3CDS | ENST00000478654 | ENST00000388768 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000478654 | ENST00000602465 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000478654 | ENST00000265865 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000478654 | ENST00000399200 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000478654 | ENST00000454950 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000478654 | ENST00000472394 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000478654 | ENST00000342616 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000460911 | ENST00000388768 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000460911 | ENST00000602465 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000460911 | ENST00000265865 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000460911 | ENST00000399200 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000460911 | ENST00000454950 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000460911 | ENST00000472394 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000460911 | ENST00000342616 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000350995 | ENST00000388768 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000350995 | ENST00000602465 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000350995 | ENST00000265865 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000350995 | ENST00000399200 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000350995 | ENST00000454950 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000350995 | ENST00000472394 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000350995 | ENST00000342616 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000320356 | ENST00000388768 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000320356 | ENST00000602465 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000320356 | ENST00000265865 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000320356 | ENST00000399200 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000320356 | ENST00000454950 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000320356 | ENST00000472394 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000320356 | ENST00000342616 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000541220 | ENST00000388768 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000541220 | ENST00000602465 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000541220 | ENST00000265865 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000541220 | ENST00000399200 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000541220 | ENST00000454950 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000541220 | ENST00000472394 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000541220 | ENST00000342616 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000476773 | ENST00000388768 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000476773 | ENST00000602465 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000476773 | ENST00000265865 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000476773 | ENST00000399200 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000476773 | ENST00000454950 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000476773 | ENST00000472394 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000476773 | ENST00000342616 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000483967 | ENST00000388768 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000483967 | ENST00000602465 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000483967 | ENST00000265865 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000483967 | ENST00000399200 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000483967 | ENST00000454950 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000483967 | ENST00000472394 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000483967 | ENST00000342616 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000536783 | ENST00000388768 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000536783 | ENST00000602465 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-3CDS | ENST00000536783 | ENST00000265865 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000536783 | ENST00000399200 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000536783 | ENST00000454950 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000536783 | ENST00000472394 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
intron-intron | ENST00000536783 | ENST00000342616 | EZH2 | chr7 | 148504703 | + | RUFY2 | chr10 | 70136641 | + |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for EZH2-RUFY2 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for EZH2-RUFY2 |
Go to FGviewer for the breakpoints of :-: - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
EZH2 | . |
FUNCTION: Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Displays a preference for substrates with less methylation, loses activity when progressively more methyl groups are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2 (PubMed:22323599, PubMed:30923826). Compared to EZH1-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes. EZH2 can also methylate non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. Regulates the circadian clock via histone methylation at the promoter of the circadian genes. Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription. {ECO:0000269|PubMed:14532106, ECO:0000269|PubMed:15225548, ECO:0000269|PubMed:15231737, ECO:0000269|PubMed:15385962, ECO:0000269|PubMed:16179254, ECO:0000269|PubMed:16357870, ECO:0000269|PubMed:16618801, ECO:0000269|PubMed:16717091, ECO:0000269|PubMed:16936726, ECO:0000269|PubMed:17210787, ECO:0000269|PubMed:17344414, ECO:0000269|PubMed:18285464, ECO:0000269|PubMed:19026781, ECO:0000269|PubMed:20935635, ECO:0000269|PubMed:22323599, ECO:0000269|PubMed:23063525, ECO:0000269|PubMed:24474760, ECO:0000269|PubMed:30923826}. | FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for EZH2-RUFY2 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for EZH2-RUFY2 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for EZH2-RUFY2 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Hgene | EZH2 | Q15910 | DB12887 | Tazemetostat | Inhibitor | Small molecule | Approved|Investigational |
Hgene | EZH2 | Q15910 | DB12887 | Tazemetostat | Inhibitor | Small molecule | Approved|Investigational |
Top |
Related Diseases for EZH2-RUFY2 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | EZH2 | C0265210 | Weaver syndrome | 6 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Hgene | EZH2 | C0033578 | Prostatic Neoplasms | 3 | CTD_human |
Hgene | EZH2 | C0376358 | Malignant neoplasm of prostate | 3 | CTD_human |
Hgene | EZH2 | C0001815 | Primary Myelofibrosis | 1 | CTD_human |
Hgene | EZH2 | C0006142 | Malignant neoplasm of breast | 1 | CTD_human |
Hgene | EZH2 | C0007621 | Neoplastic Cell Transformation | 1 | CTD_human |
Hgene | EZH2 | C0010278 | Craniosynostosis | 1 | CTD_human |
Hgene | EZH2 | C0014170 | Endometrial Neoplasms | 1 | CTD_human |
Hgene | EZH2 | C0024301 | Lymphoma, Follicular | 1 | CGI;CTD_human |
Hgene | EZH2 | C0029463 | Osteosarcoma | 1 | CTD_human |
Hgene | EZH2 | C0030044 | Acrocephaly | 1 | CTD_human |
Hgene | EZH2 | C0043094 | Weight Gain | 1 | CTD_human |
Hgene | EZH2 | C0079744 | Diffuse Large B-Cell Lymphoma | 1 | CGI;CTD_human;UNIPROT |
Hgene | EZH2 | C0079745 | Lymphoma, Large-Cell, Follicular | 1 | CTD_human |
Hgene | EZH2 | C0079758 | Lymphoma, Mixed-Cell, Follicular | 1 | CTD_human |
Hgene | EZH2 | C0079765 | Lymphoma, Small Cleaved-Cell, Follicular | 1 | CTD_human |
Hgene | EZH2 | C0221356 | Brachycephaly | 1 | CTD_human |
Hgene | EZH2 | C0265534 | Scaphycephaly | 1 | CTD_human |
Hgene | EZH2 | C0265535 | Trigonocephaly | 1 | CTD_human |
Hgene | EZH2 | C0333704 | Chromosome Breaks | 1 | CTD_human |
Hgene | EZH2 | C0349639 | Juvenile Myelomonocytic Leukemia | 1 | CTD_human |
Hgene | EZH2 | C0376628 | Chromosome Breakage | 1 | CTD_human |
Hgene | EZH2 | C0476089 | Endometrial Carcinoma | 1 | CTD_human |
Hgene | EZH2 | C0678222 | Breast Carcinoma | 1 | CTD_human |
Hgene | EZH2 | C0749794 | Upper Extremity Deformities, Congenital | 1 | CTD_human |
Hgene | EZH2 | C1257931 | Mammary Neoplasms, Human | 1 | CTD_human |
Hgene | EZH2 | C1301355 | Myelodysplastic-Myeloproliferative Diseases | 1 | CTD_human |
Hgene | EZH2 | C1458155 | Mammary Neoplasms | 1 | CTD_human |
Hgene | EZH2 | C1833340 | Synostotic Posterior Plagiocephaly | 1 | CTD_human |
Hgene | EZH2 | C1860789 | Leukemia, Megakaryoblastic, of Down Syndrome | 1 | CTD_human |
Hgene | EZH2 | C1860819 | Metopic synostosis | 1 | CTD_human |
Hgene | EZH2 | C1956130 | Lymphoma, Follicular, Grade 1 | 1 | CTD_human |
Hgene | EZH2 | C1956131 | Lymphoma, Follicular, Grade 3 | 1 | CTD_human |
Hgene | EZH2 | C1956132 | Lymphoma, Follicular, Grade 2 | 1 | CTD_human |
Hgene | EZH2 | C2239176 | Liver carcinoma | 1 | CTD_human |
Hgene | EZH2 | C2713368 | Hematopoetic Myelodysplasia | 1 | CTD_human |
Hgene | EZH2 | C2931150 | Synostotic Anterior Plagiocephaly | 1 | CTD_human |
Hgene | EZH2 | C3463824 | MYELODYSPLASTIC SYNDROME | 1 | CTD_human |
Hgene | EZH2 | C4551902 | Craniosynostosis, Type 1 | 1 | CTD_human |
Hgene | EZH2 | C4704874 | Mammary Carcinoma, Human | 1 | CTD_human |